News & Events
- Seres Therapeutics Announces Chief Executive Officer Transition
- Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
- Vedanta Biosciences Raises $27 Million Series C Financing to Advance Clinical Pipeline of Microbiome-Derived Product Candidates
- Vedanta Biosciences Initiates Phase 2 Study for Lead Rationally-Defined Bacterial Consortium Product Candidate, VE303
- Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
- Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for Inflammatory Bowel Disease
- Pioneer of the Year award – Silvia Caballero!
- Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
- Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
- Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
- Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
- Vedanta Biosciences Announces Preclinical Data on Microbiome-Derived Immuno-Oncology Candidate
- Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
- Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
- Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical Officer